Human HER2 ELISA Kit0 Publications

Catalog number: KE00053



96 T


Images See all


Product name:
Human HER2 ELISA Kit

1 X 96 well plate

Sample type:
Serum, Plasma, Cell culture supernatant, Urine

Assay type:

0.02 ng/mL

0.156-10 ng/mL

Reacted Species:

Tested applications:
Sandwich ELISA

Sample TypeAverageRange
Cell culture supernatant 99% 92%-108%
Urine 102% 91%-121%
Human plamsa 87% 75%-100%

Samplenmean (ng/mL)SDCV%
1 20 7,741.5 307.1 4.0
2 20 1,528.3 54.3 3.6
3 20 411.4 14.1 3.4

Samplenmean (ng/mL)SDCV%
1 24 6,807.4 365.4 5.4
2 24 1,423.2 68.5 4.8
3 24 353.5 20.7 5.9

Product overview:
KE00053 is a solid phase sandwich Enzyme Linked-Immuno-Sorbent Assay (Sandwich ELISA). The HER2 ELISA kit is to be used to detect and quantify protein levels of endogenous HER2. The assay recognizes human HER2. A polyclonal antibody specific for HER2 has been pre-coated onto the microwells. The HER2 protein in samples is captured by the coated antibody after incubation. Following extensive washing, a monoclonal antibody specific for HER2 is added to detect the captured HER2 protein. For signal development, horseradish peroxidase (HRP)-conjugated antibody is added, followed by Tetramethyl-benzidine (TMB) reagent. Solution containing sulfuric acid is used to stop color development and the color intensity which is proportional to the quantity of bound protein is measurable at 450nm.


Storage Instructions:
All the reagents are stored at 2-8℃. Refer to the protocol for further storage instructions.

CD340, ERBB2, ERBB2,p185-Specific, HER 2, HER 2/neu, HER2, MLN 19, MLN19, NEU, NGL, p185, p185erbB2, Proto oncogene c ErbB 2, Proto oncogene Neu, TKR1

HER2, also known as ErbB2 and Neu, is a member of the epidermal growth factor (EGF) receptor family. Overexpression of HER2 have been reported in numerous cancers, including breast, ovarian, lung, gastric, and oral cancers. It is a therapeutic target for the treatment of breast cancer and other carcinomas. HER2 is a 185-kDa transmembrane glycoprotein, the extracellular domain (ECD) of which can be cleaved from the cell surface by matrix metalloproteases and then released into blood. Elevated serum HER2 levels are reported in 23% to 80% of patients with metastatic breast cancer. Raising serum HER2 levels have been correlated with indicators of poor prognosis and a poor response to chemotherapy.

to top